Skip to content
AnalystLens

UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Oct 13, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 13, 2026
Period End
October 13, 2026
Security
UNH
In the record · 2016–202610-K1110-Q328-K173

UNH filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 173 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Feb ’22Feb ’22
  2. Leadership change8-K · Nov ’25Nov ’25

01—Abstract

Summary

Summary of the 8-K filed October 13, 2026. Cited figures are marked; the original filing is the authoritative source.

UnitedHealth Group (UNH) reported third quarter 2026 results on October 13, 2026, with consolidated revenues of $112.7 billiona (versus $113.2 billion a year earlier), earnings from operations of $6.6 billion (up from $4.3 billion), and a net margin of 3.6%.

GAAP diluted EPS was $4.56b and adjusted EPS was $4.69, compared with $2.59 and $2.92 in the year-ago quarter. The improvement was driven primarily by a lower medical care ratio of 88.4% (versus 89.9%), which included $610 million of favorable prior-period reserve development, and an operating cost ratio that fell to 12.8% from 13.5%. Cash flow from operations was $5.1 billion, or 1.2x net income.

Management raised its full-year 2026 outlook to at least $19.50c GAAP EPS and at least $20.50 adjusted EPS. Segment performance was mixed. UnitedHealthcare revenue declined to $86.3 billion, but operating margin improved to 3.3% from 2.1%, and membership fell to 48.3 million, with Medicare Advantage and Medicaid enrollment both contracting.

Optum revenue fell to $66.9 billiond, largely because Optum Health revenue dropped 10% as it exited markets lacking sufficient value-based care scale. Optum Health's earnings rebounded to $735 million from $41 million, Optum Insight grew revenue 3% to $5.5 billion, and Optum Rx earnings rose to $1.7 billion even as adjusted scripts declined to 393 million. Management also paired the results with a set of affordability, prior-authorization, and governance commitments, including a $1 billion United Health Foundation pledge.

Investors should weigh the strong margin recovery against the shrinking membership base and the fact that part of the earnings lift came from favorable reserve development, which may not recur. Balance-sheet metrics show the company continuing to return capital while deleveraging only gradually. The debt-to-capital ratio rose to 41.7% from 41.2% in the prior quarter, above management's target of about 40.0% by year-end.

Year-to-date, the company repurchased $5.0 billion of stock and paid $6.2 billion in dividends. Non-GAAP adjustments exclude intangible amortization, South American divestiture impacts, and certain restructuring items, so GAAP and adjusted figures should be reviewed together.

02—Key points

Key Highlights

  1. Q3 2026 earnings from operations rose to $6.6 billion from $4.3 billion a year earlier, on revenue of $112.7 billion (down from $113.2 billion).
  2. GAAP diluted EPS was $4.56 and adjusted EPS was $4.69, versus $2.59 and $2.92 in Q3 2025.
  3. Medical care ratio improved to 88.4% from 89.9%, including $610 million of favorable prior-period reserve development; operating cost ratio fell to 12.8% from 13.5%.
  4. Full-year 2026 outlook raised to at least $19.50 GAAP EPS and at least $20.50 adjusted EPS.
  5. Cash flow from operations of $5.1 billion equaled 1.2x net income; year-to-date buybacks were $5.0 billion and dividends $6.2 billion.
  6. Debt-to-capital ratio rose to 41.7% from 41.2% in Q2 2026, still above the ~40.0% year-end target.
  7. Membership contracted across segments: UnitedHealthcare served 48.3 million people, Medicare Advantage fell 935,000 since year-end 2025, and Optum Health revenue fell 10% year over year.

03—Questions

Frequently Asked Questions

  1. Why did earnings improve so much despite lower revenue?

    The improvement came mainly from margin gains rather than top-line growth. The medical care ratio fell 150 basis points to 88.4%, aided by $610 million of favorable prior-period reserve development, and the operating cost ratio fell 70 basis points to 12.8%. Benefit design changes, pricing discipline, and lower Optum Health losses also contributed.

  2. How much of the quarter's earnings came from one-time or non-recurring items?

    The $610 million of favorable reserve development is a notable non-recurring benefit that flatters the medical cost ratio. Adjusted EPS excludes intangible amortization, South American divestiture impacts, and restructuring items, but it does not strip out reserve development. Investors should evaluate how much of the margin improvement reflects underlying trends versus reserve releases.

  3. Is the raised full-year guidance a reliable signal?

    The guidance raise reflects results through the third quarter, which is a reasonable basis for an updated outlook. However, the full year still depends on fourth-quarter medical cost trends and on the reserve development recognized so far. Investors should watch whether the company sustains its medical cost ratio in the coming quarters.

  4. Is membership decline a concern for UnitedHealth's growth?

    Yes. UnitedHealthcare membership fell to 48.3 million from 50.1 million a year earlier, driven by employer attrition, Medicaid eligibility changes, and Medicare Advantage contraction. Management is trading volume for margin and pricing discipline, so revenue may remain pressured even as profitability improves.

  5. What are the capital allocation implications?

    The company is still returning substantial cash through buybacks and dividends, but the debt-to-capital ratio edged up to 41.7%, above the roughly 40.0% year-end target. Hitting that target will likely require debt reduction or continued earnings growth, which constrains how much capital can be returned without further leverage progress.

04—Continue

← View all 8-K filings